Technical Analysis for URGN - UroGen Pharma Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 14.50 | 0.28% | 0.04 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Hammer Candlestick | Bullish | 0.00% | |
Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% |
Alert | Time |
---|---|
Possible NR7 | about 17 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
1.5x Volume Pace | about 21 hours ago |
Down 3% | about 21 hours ago |
Down 2 % | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 03/14/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Oab Botulinum Toxin Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 24.13 |
52 Week Low | 7.75 |
Average Volume | 301,355 |
200-Day Moving Average | 14.69 |
50-Day Moving Average | 16.63 |
20-Day Moving Average | 17.43 |
10-Day Moving Average | 16.76 |
Average True Range | 1.10 |
RSI (14) | 32.89 |
ADX | 27.44 |
+DI | 11.27 |
-DI | 34.29 |
Chandelier Exit (Long, 3 ATRs) | 16.58 |
Chandelier Exit (Short, 3 ATRs) | 17.12 |
Upper Bollinger Bands | 20.12 |
Lower Bollinger Band | 14.74 |
Percent B (%b) | -0.04 |
BandWidth | 30.88 |
MACD Line | -0.47 |
MACD Signal Line | 0.05 |
MACD Histogram | -0.5251 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 15.63 | ||||
Resistance 3 (R3) | 15.53 | 15.06 | 15.44 | ||
Resistance 2 (R2) | 15.06 | 14.77 | 15.11 | 15.38 | |
Resistance 1 (R1) | 14.78 | 14.59 | 14.88 | 14.88 | 15.32 |
Pivot Point | 14.30 | 14.30 | 14.35 | 14.35 | 14.30 |
Support 1 (S1) | 14.02 | 14.01 | 14.12 | 14.12 | 13.68 |
Support 2 (S2) | 13.55 | 13.84 | 13.60 | 13.62 | |
Support 3 (S3) | 13.27 | 13.55 | 13.56 | ||
Support 4 (S4) | 13.37 |